Postural tachycardia syndrome (POTS) and antiphospholipid syndrome (APS): What do we know so far?
Anticoagulation
Antiphospholipid antibodies
Antiphospholipid syndrome
Autonomic dysfunction
Cytokines
Postural orthostatic tachycardia syndrome
Journal
Revue neurologique
ISSN: 0035-3787
Titre abrégé: Rev Neurol (Paris)
Pays: France
ID NLM: 2984779R
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
24
08
2021
revised:
05
10
2021
accepted:
05
10
2021
pubmed:
14
12
2021
medline:
17
5
2022
entrez:
13
12
2021
Statut:
ppublish
Résumé
As part of the non-criteria clinical manifestations, postural orthostatic tachycardia syndrome (POTS), a multisystem autonomic dysfunction, can co-exist with antiphospholipid syndrome (APS). Several pieces of evidence hint on the autoimmune basis of POTS, and its possible association with several autoimmune diseases, including APS. Indeed, the evidence exists in the etiologies, symptomatology, and treatment options. Although infections, viral ones in particular, stress, and pregnancy are etiologies to both POTS and APS, the exact pathophysiological connection is still to be studied taking into consideration the activity of cytokines in both diseases. Nevertheless, certain immunomodulatory treatments used for the catastrophic or obstetrical forms of APS, such as intravenous immunoglobulins (IVIG) and steroids, have been also used for the treatment of POTS resistant to classical treatments. Therefore, our review aims to highlight the association between POTS and APS, shedding light on the common etiologies explaining the pathophysiology of the two disorders, the diagnostic approach to POTS as a possible clinical criterion of APS, and the treatment of APS in the context of treating POTS.
Identifiants
pubmed: 34895744
pii: S0035-3787(21)00772-4
doi: 10.1016/j.neurol.2021.10.006
pii:
doi:
Substances chimiques
Immunoglobulins, Intravenous
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
306-314Informations de copyright
Copyright © 2021 Elsevier Masson SAS. All rights reserved.